Abstract |
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.
|
Authors | Jason E Faris, M Dror Michaelson |
Journal | Nature reviews. Clinical oncology
(Nat Rev Clin Oncol)
Vol. 7
Issue 1
Pg. 7-8
(Jan 2010)
ISSN: 1759-4782 [Electronic] England |
PMID | 20029441
(Publication Type: Comment, Journal Article)
|